Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Apr;46(3):473-479.
doi: 10.1111/ced.14502. Epub 2020 Dec 5.

News on infantile haemangioma. Part 1: clinical course and pathomechanism

H De Leye  1 , J Saerens  1 , S R Janmohamed  1
Affiliations
Review

News on infantile haemangioma. Part 1: clinical course and pathomechanism

H De Leye et al. Clin Exp Dermatol. 2021 Apr.

Abstract

Currently, there is no doubt that the first choice of treatment for alarming infantile haemangiomas (IHs) is oral beta-blockers. However, research in this field remains active, as the pathogenesis of IH is still not completely elucidated. Furthermore, there are different approaches to the management of IHs with beta-blockers. In Part 1 of this review we will discuss the state-of-the-art evidence for IH with regard to (i) the definition, epidemiology, course, risk factors and sequelae, and (ii) the pathogenesis, focusing on genetic studies. This review will update the reader on the latest developments in the pathogenesis of IH. Furthermore, we hope this review will give more insight into risk factors and sequelae of IH, thereby contributing to better decisions in the clinical management of patients with IH. The therapy and evaluation of IHs will be discussed in Part 2 of this review.

PubMed Disclaimer

References

    1. Wassef M, Blei F, Adams D et al. Vascular anomalies classification: recommendations from the International Society for the Study of Vascular Anomalies. Pediatrics 2015; 136: e203-14.
    1. Ding Y, Zhang JZ, Yu SR, et al. Risk factors for infantile hemangioma: a meta-analysis. World J Pediatr 2019; 16: 377-84.
    1. Leaute-Labreze C, Harper JI, Hoeger PH. Infantile haemangioma. Lancet 2017; 390: 85-94.
    1. Luu M, Frieden IJ. Haemangioma: clinical course, complications and management. Br J Dermatol 2013; 169: 20-30.
    1. Haggstrom AN, Drolet BA, Baselga E et al. Prospective study of infantile hemangiomas: clinical characteristics predicting complications and treatment. Pediatrics 2006; 118: 882-7.